Fosnight described how stigma itself becomes a barrier to care, even though effective diagnostic and treatment options are available. In an interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, ...

FG-3246 targets CD46 in mCRPC patients, focusing on those who progressed on ARSI without prior taxane therapy. The trial will evaluate FG-3246's safety, efficacy, and pharmacokinetics, alongside ...

A major focus of the discussion is the integration of advanced prostate cancer therapeutics into urology offices. In this episode of Pearls and Perspectives, Amy Pearlman, MD, speaks with Vahan ...

Ensuring consistent diagnostic quality remains critical. In this video, Veeru Kasivisvanathan, MBBS, BSc, FRCS, MSc, PGCert, PhD, discussed findings from the PRIME trial, a multicenter international ...

Stephen J. Freedland, MD, placed dietary guidance within the broader context of survivorship care. In discussing the links between diet and prostate cancer, Stephen J. Freedland, MD, a professor of ...

Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC. On September 9, 2025, the FDA approved the gemcitabine intravesical system ...

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.

Adding the investigational agent masitinib to standard frontline docetaxel significantly reduced the risk of disease progression or death in men with metastatic castration-resistant prostate cancer ...

Miles-Thomas emphasized the importance of Northwestern’s thoughtful implementation strategy. In a recent interview, Henry C. Wright IV, MD, and Jennifer Miles-Thomas, MD, URPS, MBA, highlighted ...

The combination of olaparib and radium-223 improved rPFS in CRPC patients with bone metastases compared to radium-223 alone. The greatest benefit was observed in patients without prior docetaxel ...

Inlexzo, a gemcitabine intravesical system, is approved for BCG-unresponsive NMIBC, offering extended local drug delivery for up to 14 cycles. The SunRISe-1 trial showed an 82.4% complete response ...

Prostate cancer incidence rates have increased by 3% annually since 2014, with advanced-stage diagnoses rising by 4.6% to 4.8% per year. Mortality rate declines have slowed to 0.6% annually, with ...